What Is MT-2 (The Barbie Peptide)? How It Works + What To Expect

You've probably heard of tesamorelin, and it's often been called the visceral fat peptide. It's the most expensive growth hormone-related peptide option out there, and it basically works the same way as CJC1295 and somerellin.

It runs through the same pathway and the same mechanism as those cheaper options, so the question worth answering is whether the price buys you anything they don't already do.

Before any of that, this is not medical advice, and you should talk to a licensed physician before you put anything into your body.

It's a synthetic 44-amino acid analog of growth hormone-releasing hormone, or GHRH. It was FDA approved back in 2010 under the brand name Agrifda for HIV-associated visceral fat reduction. I'll say plainly that those two facts come from the product labeling and the history of the drug rather than from a study I can hand you, so take them as background, not as evidence of anything.

Tessemorellin is in the same family as CJC1295 and somerellin, but it's engineered differently, and it's the most expensive growth hormone-related peptide out there.

Now, to understand how tessemorellin actually works, you need to understand how your body's natural growth hormone and IGF-1 pathway works. There's a two-stage process here that most people never get explained to them, and if you skip it, every dosing decision you make afterward is a guess.

Stage one is when your hypothalamus produces a hormone called growth hormone-releasing hormone, or GHRH. That GHRH signals your pituitary gland to release growth hormone. GHRH does this by binding a receptor on the pituitary that runs through a cyclic AMP cascade, which is a chain of internal chemical messengers that both dumps stored growth hormone and tells the cell to make more of it (Halmos 2025).

There's a second signal working alongside that first one, coming from your stomach, which produces a hormone called ghrelin, and that ghrelin amplifies the GHRH signal through a completely separate receptor (Kojima 1999).

Think of it as two different doors into the same room, and opening just one gets you a pulse of growth hormone, while opening both at once produces something much bigger than either door alone would give you, which is why your biggest natural growth hormone release happens during deep sleep when you're fasted and both signals are firing (Devesa 2021).

From there the process moves into its second stage, where that growth hormone travels to your liver, and your liver is what converts it into IGF-1, insulin-like growth factor one.

IGF-1 handles the actual work behind fat mobilization, muscle repair, recovery, and collagen production.

There's a catch that shapes the entire dosing conversation. In my experience working with clients, that liver conversion runs much better when insulin is present, and I've never found a clean study that nails down exactly how much insulin you need or when, so treat that as a working model rather than settled science.

Because your best growth hormone release happens fasted and your best conversion to IGF-1 happens fed, those two things can't occur at the same moment, and that mismatch is exactly what creates a scheduling problem your body has to work around.

Sleep solves it through timing. You sleep fasted and get a large overnight pulse, that growth hormone circulates for a few hours, and then breakfast raises insulin and the liver does the conversion.

You can manipulate this system in roughly four ways. You can inject growth hormone directly, which bypasses the signal system entirely and produces a flat elevation instead of a pulse, and it carries more insulin resistance, water retention, and carpal tunnel risk. Whether that flat elevation suppresses your own production over time is something I've heard repeated constantly and never seen properly demonstrated in a trial, so I hold it loosely.

You can inject IGF-1 directly, which skips every regulatory checkpoint your body has and carries the highest risk of the four.

You can use GHRH analogs, which is tesamorelin, CJC1295, and sermorelin. These mimic the hypothalamic signal, so your pituitary releases your own growth hormone and your feedback loops stay intact, though the tradeoff is that they hit only that single pathway.

Or you use GHRPs, growth hormone-releasing peptides, things like ipamorelin, GHRP2, and GHRP6, which work the ghrelin receptor instead. That receptor was mapped years before ghrelin itself was discovered, which is why the early synthetic secretagogues worked on a pathway nobody could name yet (Baldelli 2001).

And that's why it's very common for you to see GHRH analogs and GHRPs stacked together so that we hit both pathways at the same time. The most common version is CJC1295 with ipamorelin.

And that's exactly why it's so popular. You're hitting both the GHRH pathway and the ghrelin pathway, which means that you get a much larger growth hormone pulse than either one alone, and this does a really good job of most closely mimicking your natural production of growth hormone and IGF-1.

After you inject it subcutaneously, it's gonna absorb very rapidly, and the peak blood concentration actually happens in about 30 minutes to an hour after that injection. The half-life is only about 26 minutes, which is why the drug is gone from your blood long before the effect is.

That short window still produces a two to three hour growth hormone burst from the pituitary, and IGF-1 climbs gradually behind it, stabilizing over two to four weeks of daily use. Fast clearance is exactly why this is a daily injection and not a twice-weekly one.

Once IGF-1 is elevated it activates hormone-sensitive lipase, the enzyme that breaks fat down for energy. Tesomerellin is also gonna help to drive muscle protein synthesis, collagen production, bone density maintenance, and it crosses the blood-brain barrier, which means it supports cognitive function.

You've heard Tesomerellin called the visceral fat peptide, and you're probably wondering, well, if it works the same way as CJC1295 and sermerellin, what makes it specifically target visceral fat? Here's the truth.

Every GHRH analog signals the pituitary the same way, the growth hormone raises IGF-1, and IGF-1 mobilizes fat through lipolysis, so the underlying process is identical across the whole class. There is no visceral fat receptor that tesamorelin hits and the others miss, and fat mobilization does not read a map before it starts working.

The paperwork is what separates them. The HIV lipodystrophy trials measured visceral fat with CT scans over 26 weeks, which is what tesamorelin was built and approved for. CJC1295 and ipamorelin were looked at for sleep, recovery, and general body composition, never with abdominal CT as the endpoint.

Sermorelin is the older molecule at 29 amino acids against tesamorelin's 44, less stable, and it produces cortisol and prolactin spikes that tesamorelin does not.

Whether tesamorelin actually reduces visceral fat better, or simply carries the only CT scan data proving it in that specific population, is a question worth sitting with. The honest answer is we don't know, because that comparison study doesn't exist.

Could you get the same visceral fat reduction from CJC1295 dosed consistently at two milligrams equivalent daily for 26 weeks? Probably, but we don't have that data to prove it.

Clinical-grade compounded tesamorelin runs $1,000 to $1,200 a month, and research sources land at $300 to $500. And if you were to compare that to CJC and hypermerellin stacked together, the clinical grade is gonna be about half of that, and the research grade is gonna be about $1 to $200.

And here's my honest opinion on the cost. If you're gonna spend over $1,000 a month on a growth hormone analog, you might as well just buy growth hormone and do that.

It's more direct, more studied, and more predictable, and the one thing tesamorelin holds onto that plain growth hormone doesn't is your natural feedback loops.

But at that price point, the cost doesn't make sense for most people unless you specifically wanna maintain those natural rhythms. For most goals, CJC and ipamorelin ends up the better value at roughly a third of the price for the same mechanism.

The approval trials used two milligrams subcutaneously once daily for 26 weeks, and patients saw 15 to 20% visceral adipose tissue reduction on CT while preserving lean body mass. Triglycerides fell around 50 points, cholesterol dropped about 30%, some fatty liver cases improved, and IGF-1 rose into the mid-normal range for age.

Those patients had severe metabolic dysfunction and extreme visceral accumulation to begin with, and the results held only while they stayed on the drug, with some fat returning after stopping. If your habits don't change, the peptide is temporary relief.

A study published in JCI Insight showed improved cognitive function and brain metabolism in older adults at risk for Alzheimer's. And this is why the anti-aging community has latched onto this, because we see IGF-1 decline with age, and restoring it to mid or normal range seems to have protective effects.

Research: Kojima 1999; Halmos 2025; Devesa 2021; Baldelli 2001; Gesmundo 2025; Zhu 2023.

References:

Kojima M, Hosoda H, Date Y et al.. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999. https://pubmed.ncbi.nlm.nih.gov/10604470/

Gesmundo I, Pedrolli F, Cai R et al.. Growth hormone-releasing hormone and cancer. Rev Endocr Metab Disord. 2025. https://pubmed.ncbi.nlm.nih.gov/39422787/

Halmos G, Szabo Z, Dobos N et al.. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev Endocr Metab Disord. 2025. https://pubmed.ncbi.nlm.nih.gov/39934495/

Devesa J. The Complex World of Regulation of Pituitary Growth Hormone Secretion: The Role of Ghrelin, Klotho, and Nesfatins in It. Front Endocrinol (Lausanne). 2021. https://pubmed.ncbi.nlm.nih.gov/33776931/

Baldelli R, Otero XL, Camiña JP et al.. Growth hormone secretagogues as diagnostic tools in disease states. Endocrine. 2001. https://pubmed.ncbi.nlm.nih.gov/11322508/

Zhu Y, Negishi R, Fukunaga K et al.. Activation of the growth-IGF-1 axis, but not appetite, is related to high growth performance in juveniles of the Malabar grouper, Epinephelus malabaricus, under isosmotic condition. Comp Biochem Physiol A Mol Integr Physiol. 2023. https://pubmed.ncbi.nlm.nih.gov/37269939/